8-K: TenX Keane Acquisition Extends Merger Deadline with $66,667 Deposit

TenX Keane Acquisition secured a one-month extension to complete its business combination by receiving a $66,667 deposit from Citius Pharmaceuticals.

Summary

• TenX Keane Acquisition has extended its deadline to complete a business combination by one month, from April 18, 2024, to May 18, 2024.
• This extension was secured through a $66,667 deposit made by Citius Pharmaceuticals, acting as the designee of the company's sponsor, 10XYZ Holdings LP.
• The deposit is structured as an unsecured promissory note from TenX Keane Acquisition to Citius Pharmaceuticals.
• The note bears no interest and is repayable upon the completion of the business combination, provided the trust account balance is at least $2,000,000.
• The company has the option to extend the deadline up to seven times, each for an additional month, until November 18, 2024, with similar monthly deposits.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the extension provides more time, it also highlights the ongoing challenges in completing the business combination. The terms of the extension are standard, but the unsecured nature of the note and the trust account threshold introduce some uncertainty.

Positives

• The company has successfully extended the deadline for its business combination, providing more time to finalize the deal.
• The funding mechanism for the extension is clearly defined and secured through a promissory note.
• The agreement allows for multiple extensions, providing flexibility in the timeline.

Negatives

• The extension requires a monthly deposit, which could be a recurring cost if the business combination is not completed quickly.
• The promissory note is unsecured, which could pose a risk to Citius Pharmaceuticals if the business combination fails and the trust account does not meet the minimum threshold.
• The repayment of the note is contingent on the trust account balance reaching $2,000,000 at the time of closing, which introduces uncertainty.

Risks

• The business combination may not be completed by the extended deadline, requiring further extensions and additional deposits.
• The trust account may not reach the $2,000,000 threshold, potentially delaying or preventing the repayment of the promissory note.
• The unsecured nature of the promissory note exposes Citius Pharmaceuticals to potential losses if the business combination fails.

Future Outlook

TenX Keane Acquisition has the option to extend the business combination deadline up to six more times, each for an additional month, until November 18, 2024, subject to additional monthly deposits.

Management Comments

• Xiaofeng Yuan, Chief Executive Officer and Chairman, signed the report on behalf of TenX Keane Acquisition.

Industry Context

The use of a special purpose acquisition company (SPAC) like TenX Keane Acquisition to acquire another company is a common practice, and the extension of deadlines is not unusual in such transactions. The need for extensions can reflect the complexities of the deal or challenges in securing the necessary funding or approvals.

Comparison to Industry Standards

• The structure of the extension, involving a monthly deposit and a promissory note, is a typical mechanism used by SPACs to extend their timelines.
• The $66,667 deposit is relatively small compared to the overall size of many SPAC transactions, but it is consistent with the terms outlined in the company's charter.
• The requirement for a $2,000,000 trust account balance for repayment is a common safeguard to ensure sufficient funds are available for the business combination.
• Other SPACs, such as those formed by experienced sponsors like Pershing Square Tontine Holdings, have also faced similar challenges in completing their business combinations and have used similar extension mechanisms.

Related Party Transactions

• The promissory note issued to Citius Pharmaceuticals is a related party transaction, as Citius Pharmaceuticals is the designee of the company's sponsor.

Stakeholder Impact

• Shareholders of TenX Keane Acquisition are impacted by the extension, as it delays the completion of the business combination.
• Citius Pharmaceuticals is impacted as they are providing the funding for the extension and are subject to the terms of the promissory note.
• The sponsor, 10XYZ Holdings LP, is impacted as they are responsible for the monthly deposits.

Next Steps

• TenX Keane Acquisition will continue to work towards completing its business combination by the new deadline of May 18, 2024.
• The company may need to secure additional extensions and deposits if the business combination is not completed by the new deadline.
• Citius Pharmaceuticals will monitor the progress of the business combination and the trust account balance to ensure repayment of the promissory note.

Key Dates

Keywords

business combination, merger, promissory note, extension, trust account, Citius Pharmaceuticals, TenX Keane Acquisition, deadline